Remdesivir treatment for patients with moderate to severe COVID-19
Authors:
- İmRan HasanoğluIHİmRan Hasanoğlu
- Hati̇cE Rahmet GünerHGHati̇cE Rahmet Güner
- İlHami̇ Çeli̇kIÇİlHami̇ Çeli̇k
- Fi̇kRet KanatFKFi̇kRet Kanat
- Ayşe BatirelABAyşe Batirel
- Gülçi̇n Telli̇ Di̇zManGDGülçi̇n Telli̇ Di̇zMan
- Esma Eryilmaz ErenEEEsma Eryilmaz Eren
- Di̇lEk Yildiz Sevgi̇DSDi̇lEk Yildiz Sevgi̇
- Kadri̇yE Kart YaşarKYKadri̇yE Kart Yaşar
- Sevtap ŞenoğluSŞSevtap Şenoğlu
- Esra KazakEKEsra Kazak
Open Access
- 1 January 2022
- journal article
- research article
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 52 (4) , 880-887
Abstract
Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment. Materials and methods: This multicenter prospective observational study was conducted in 14 centers in Turkey. Pregnancy or breastfeeding, multiorgan failure, or usage of vasopressors for septic shock, ALT > 5 × the upper limit of the normal range, or eGRFKeywords
This publication has 22 references indexed in Scilit:
- Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysisLife Sciences, 2021
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19New England Journal of Medicine, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation statusPharmacological Research, 2020
- Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy SubjectsClinical and Translational Science, 2020
- Compassionate Use of Remdesivir for Patients with Severe Covid-19New England Journal of Medicine, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Comparative Outcomes of Adults Hospitalized With Seasonal Influenza A or B Virus Infection: Application of the 7-Category Ordinal ScaleOpen Forum Infectious Diseases, 2019
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017